Skip to main content
Article thumbnail
Location of Repository

Differential sensitivity of basal and acetylcholine-induced activity of nitric oxide to blockade by asymmetric dimethylarginine (ADMA) in the rat aorta

By M.J. AL-Zobaidy, J. Craig and W. Martin


<b>Background and purpose</b>: Previous work has shown that NG-monomethyl-l-arginine (l-NMMA) paradoxically inhibits basal, but not ACh-stimulated activity of nitric oxide in rat aorta. The aim of this study was to determine if the endogenously produced agent, asymmetric NG, NG-dimethyl-l-arginine (ADMA), also exhibits this unusual selective blocking action.\ud \ud <b>Experimental approach</b>: The effect of ADMA on basal nitric oxide activity was assessed by examining its ability to enhance phenylephrine (PE)-induced tone in endothelium-containing rings. Its effect on ACh-induced relaxation was assessed both in conditions where ADMA greatly enhanced PE tone and where tone was carefully matched with control tissues at a range of different levels.\ud \ud <b>Key results</b>: ADMA (100 µM) potentiated PE-induced contraction, consistent with inhibition of basal nitric oxide activity. Higher concentrations (300–1000 µM) had no greater effect. Although ADMA (100 µM) also appeared to block ACh-induced relaxation when it enhanced PE tone to maximal levels, virtually no block was seen at intermediate levels of tone in the presence of ADMA. Even ADMA at 1000 µM had no effect on the maximal relaxation to ACh, although it produced a small (two- to threefold) reduction in sensitivity. ADMA and l-NMMA, like l-arginine (all at 1000 µM), protected ACh-induced relaxation against blockade by l-NAME (30 µM).\ud \ud <b>Conclusions and implications</b>: In the rat aorta, ADMA, like l-NMMA, blocks basal activity of nitric oxide, but has little effect on that stimulated by ACh. Further studies are required to explain these seemingly anomalous actions of ADMA and l-NMMA

Topics: QH345
Publisher: Wiley-Blackwell
Year: 2010
OAI identifier:
Provided by: Enlighten

Suggested articles


  1. (1989). A specific inhibitor of nitric oxide formation form L-arginine attenuates endothelium-dependent relaxations. doi
  2. (1992). Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. doi
  3. (1993). Actions and interactions of N G-substituted analogues of L-arginine on NANC neurotransmission in the bovine retractor penis and rat anococcygeus muscles. doi
  4. (1983). Agonist-induced endothelium-dependent relaxation may be mediated through cyclic GMP. doi
  5. (2000). An indirect influence of phenylephrine on the release of endothelium-derived vasodilators in rat small mesenteric artery. doi
  6. (2007). Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. doi
  7. (1998). Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction - Its role in hypercholesterolemia. doi
  8. (1996). Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. doi
  9. (1990). Characterisation of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. doi
  10. (1986). Depression of contractile responses in rat aorta by spontaneously released endotheliumderived relaxing factor.
  11. (2007). Differential effects of nitric oxide synthase inhibitors on endothelium-dependent and nitrergic nerve-mediated vasodilatation in the bovine ciliary artery. doi
  12. (1989). Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. doi
  13. (1991). Effects of N G-substituted analogues of L-arginine on NANC relaxation of the rat anococcygeus and bovine retractor penis muscles and the bovine penile artery. doi
  14. (1998). Elevation of an endogenous inhibitor of nitric oxide synthesis in experimental congestive heart failure.
  15. (1985). Endothelial α2-adrenoceptors in canine pulmonary and systemic blood vessels. doi
  16. (1983). Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. doi
  17. (1999). Identification of flowdependent endothelial nitric-oxide synthase phosphorylation sites by mass 17spectrometry and regulation of phosphorylation and nitric oxide production by the phosphatidylinositol 3-kinase inhibitor LY294002.
  18. (1999). Inhibition of nitric oxide synthase as a potential therapeutic target. doi
  19. Isometric contraction induces the Ca 2+-independent activation of the endothelial nitric oxide synthase. doi
  20. (1990). L-N G-nitroarginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endotheliumdependent relaxation in vitro. doi
  21. (2007). Life history of eNOS: partners and pathways. doi
  22. (1992). N G-monomethyl-L-arginine causes nitric oxide synthesis in isolated arterial rings: trouble in paradise. doi
  23. (1993). N G-monomethyl-L-arginine functions as an alternative substrate and mechanism-based inhibitor of nitric oxide synthase. doi
  24. (1999). Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.
  25. (2008). Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. doi
  26. (1993). Selective inhibition of basal but not agoniststimulated activity of nitric oxide in rat aorta by N G-monomethyl-L-arginine. doi
  27. (2008). Smooth muscle α1D-adrenoceptors mediate phenylephrine-induced vasoconstriction and increases in endothelial cell Ca 2+ in hamster cremaster arterioles. doi
  28. (2006). The clinical significance of asymmetric dimethylarginine. doi
  29. (2006). The synthesis and metabolism of asymmetric dimethylarginine (ADMA). doi
  30. (1988). Vascular endothelial cells synthesise nitric oxide from L-arginine. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.